Inari Medical shares are trading lower after the company reported mixed Q4 results and disclosed a DOJ investigation. Piper Sandler downgraded the stock to Neutral.
Portfolio Pulse from Benzinga Newsdesk
Inari Medical's shares dropped following mixed Q4 results and the announcement of a DOJ investigation. Additionally, Piper Sandler downgraded the stock to Neutral.
February 29, 2024 | 6:09 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Inari Medical's stock price is likely to face downward pressure due to mixed Q4 financial results and a DOJ investigation. The downgrade by Piper Sandler to Neutral further adds to the negative sentiment.
The combination of mixed quarterly results and the announcement of a DOJ investigation typically leads to negative investor sentiment, causing stock prices to drop. The downgrade by a reputable analyst firm like Piper Sandler further validates the bearish outlook, making it likely that NARI's stock price will experience short-term downward pressure.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100